Q32 Bio Inc (QTTB)

$5.81 +0.63 (12.16%)
Market Cap 87.83M
Revenue (ttm) 53.74M
Net Income (ttm) 29.82M
EPS (ttm) N/A
PE Ratio 3.10
Forward PE N/A
Profit Margin 55.49%
Debt to Equity Ratio 0.23
Volume 644,500
Avg Vol 333,522
Day's Range N/A - N/A
Shares Out 16.96M
Stochastic %K 90%
Beta -0.05
Analysts Strong Sell
Price Target $14.33

Company Profile

Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with alopecia areata and other autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is developing Bempikibart (ADX-914), a fully human anti–interleukin-7 receptor alpha antagonist monoclonal antibody which completed Phase 2a clinical trials, designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin...

Industry: Biotechnology
Sector: Healthcare
Phone: 781 999 0232
Address:
830 Winter Street, Waltham, United States
PenkeInvesting
PenkeInvesting May. 7 at 8:22 AM
Fundamental analysis of $QTTB (Q32 Bio Inc.) based on financial data and reported results. #QTTB
0 · Reply
MaximusRadius
MaximusRadius May. 5 at 7:26 PM
$QTTB new HOD
1 · Reply
MaximusRadius
MaximusRadius May. 5 at 7:07 PM
$QTTB 10 bagger coming
0 · Reply
MaximusRadius
MaximusRadius May. 5 at 7:00 PM
$QTTB once it breaks 8.05 there is no resistance till 50.00!
0 · Reply
MaximusRadius
MaximusRadius May. 5 at 6:35 PM
$QTTB Zacks gave it a strong buy rating so apparently it has something going for it.
0 · Reply
MaximusRadius
MaximusRadius May. 5 at 5:54 PM
$QTTB broke through the 5min and 15min 50 day moving average
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser May. 4 at 7:16 PM
$QTTB RSI: 40.60, MACD: -0.1369 Vol: 0.54, MA20: 5.76, MA50: 5.83 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Kwasy32
Kwasy32 May. 4 at 5:15 PM
$QTTB mark may 7 on ur calendar
2 · Reply
The_INFO_Dude
The_INFO_Dude May. 3 at 7:19 PM
$QTTB Waiting for this to touch $4’s again so I can triple down… I’m sure most on here will despise my comment but I don’t know anyone here so.. Meh 😂
0 · Reply
EdV3
EdV3 May. 2 at 6:25 PM
$QTTB Added this one to my watchlist. IL-7 MoA looks compelling but unproven; want to see the 36 week tld first before jumping in. This should show whether the higher dosing and longer treatment period yields better results than off label JAK inhibitors. If it looks good this is definitely one to consider as the safety profile looks a lot better than existing drugs. From there the headwind is financing a registrational P3. Interesting tute activity as well with Point 72 and Opaleye opening large positions within the last quarter.
0 · Reply
Latest News on QTTB
Q32 Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 5, 2026, 6:59 AM EDT - 8 days ago

Q32 Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update

Q32 Bio Transcript: 25th Annual Needham Virtual Healthcare Conference

Apr 15, 2026, 12:45 PM EDT - 27 days ago

Q32 Bio Transcript: 25th Annual Needham Virtual Healthcare Conference

Q32 Bio to Participate in the 25th Annual Needham Virtual Healthcare Conference

Apr 8, 2026, 6:59 AM EDT - 5 weeks ago

Q32 Bio to Participate in the 25th Annual Needham Virtual Healthcare Conference

Q32 Bio Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update

Mar 10, 2026, 6:59 AM EDT - 2 months ago

Q32 Bio Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update

Q32 Bio Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 25, 2026, 2:00 PM EST - 2 months ago

Q32 Bio Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Q32 Bio initiated with a Buy at H.C. Wainwright

2026-02-25T11:12:46.000Z - 2 months ago

Q32 Bio initiated with a Buy at H.C. Wainwright

Q32 Bio to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 18, 2026, 6:59 AM EST - 2 months ago

Q32 Bio to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Q32 Bio announces $10.5M registered direct offering

2026-02-17T12:05:27.000Z - 3 months ago

Q32 Bio announces $10.5M registered direct offering

Q32 Bio Announces $10.5 Million Registered Direct Offering

Feb 17, 2026, 6:59 AM EST - 3 months ago

Q32 Bio Announces $10.5 Million Registered Direct Offering

Why Is Q32 Bio Stock (QTTB) Up Today?

2025-12-01T13:24:08.000Z - 5 months ago

Why Is Q32 Bio Stock (QTTB) Up Today?

Q32 Bio sells complement inhibitor ADX-097 to Akebia for $12M upfront

2025-12-01T12:11:17.000Z - 5 months ago

Q32 Bio sells complement inhibitor ADX-097 to Akebia for $12M upfront

AKBA

Q32 Bio sells complement inhibitor ADX-097 to Akebia

2025-12-01T12:05:21.000Z - 5 months ago

Q32 Bio sells complement inhibitor ADX-097 to Akebia

AKBA

Q32 Bio Sells Complement Inhibitor ADX-097

Dec 1, 2025, 7:00 AM EST - 5 months ago

Q32 Bio Sells Complement Inhibitor ADX-097

AKBA

Q32 Bio reports Q3 EPS (60c), consensus ($1.19)

2025-11-13T12:06:45.000Z - 6 months ago

Q32 Bio reports Q3 EPS (60c), consensus ($1.19)

Q32 Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 13, 2025, 6:59 AM EST - 6 months ago

Q32 Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Q32 Bio completes enrollment in Part B of SIGNAL-AA trial

2025-10-21T11:10:39.000Z - 7 months ago

Q32 Bio completes enrollment in Part B of SIGNAL-AA trial

Q32 Bio Announces Completion of Enrollment in Part B of SIGNAL-AA Phase 2a Clinical Trial of Bempikibart for Alopecia Areata

Oct 21, 2025, 6:59 AM EDT - 7 months ago

Q32 Bio Announces Completion of Enrollment in Part B of SIGNAL-AA Phase 2a Clinical Trial of Bempikibart for Alopecia Areata

Q32 Bio Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Sep 4, 2025, 3:45 PM EDT - 8 months ago

Q32 Bio Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Q32 Bio to Participate in the 2025 Wells Fargo Healthcare Conference

Aug 28, 2025, 6:59 AM EDT - 9 months ago

Q32 Bio to Participate in the 2025 Wells Fargo Healthcare Conference

Eight option delistings on August 18th

2025-08-18T12:30:25.000Z - 9 months ago

Eight option delistings on August 18th

ABTS BNGO HYPD TVRD ZKIN

Q32 Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 6, 2025, 6:59 AM EDT - 10 months ago

Q32 Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Q32 Bio chief medical officer Jason Campagna to depart

2025-06-25T11:06:02.000Z - 11 months ago

Q32 Bio chief medical officer Jason Campagna to depart

Q32 Bio Appoints Adrien Sipos, M.D., Ph.D., as Interim Chief Medical Officer

Jun 25, 2025, 6:59 AM EDT - 11 months ago

Q32 Bio Appoints Adrien Sipos, M.D., Ph.D., as Interim Chief Medical Officer

Oxford Biomedica completes acquisition of remaining stake in U.S. subsidiary

2025-06-23T17:06:49.000Z - 11 months ago

Oxford Biomedica completes acquisition of remaining stake in U.S. subsidiary

Q32 Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 8, 2025, 6:59 AM EDT - 1 year ago

Q32 Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update

Q32 Bio granted Fast Track designation for bempikibart

2025-04-30T11:21:23.000Z - 1 year ago

Q32 Bio granted Fast Track designation for bempikibart

Q32 Bio Announces FDA Fast Track Designation Granted to Bempikibart (ADX-914) for the Treatment of Alopecia Areata

Apr 30, 2025, 6:59 AM EDT - 1 year ago

Q32 Bio Announces FDA Fast Track Designation Granted to Bempikibart (ADX-914) for the Treatment of Alopecia Areata

Q32 Bio doses first patient in both parts of SIGNAL-AA trial

2025-04-16T11:08:11.000Z - 1 year ago

Q32 Bio doses first patient in both parts of SIGNAL-AA trial

Q32 Bio Doses First Patients in Both Part A Open-Label Extension and Part B of SIGNAL-AA Phase 2a Trial Evaluating Bempikibart in Alopecia Areata

Apr 16, 2025, 6:59 AM EDT - 1 year ago

Q32 Bio Doses First Patients in Both Part A Open-Label Extension and Part B of SIGNAL-AA Phase 2a Trial Evaluating Bempikibart in Alopecia Areata

Q32 Bio price target lowered to $15 from $16 at Wells Fargo

2025-03-12T10:30:47.000Z - 1 year ago

Q32 Bio price target lowered to $15 from $16 at Wells Fargo

Q32 Bio Transcript: Leerink Global Healthcare Conference 2025

Mar 11, 2025, 11:20 AM EDT - 1 year ago

Q32 Bio Transcript: Leerink Global Healthcare Conference 2025

Q32 Bio Reports Fourth Quarter 2024 Financial Results and Provides Corporate Update

Mar 11, 2025, 6:59 AM EDT - 1 year ago

Q32 Bio Reports Fourth Quarter 2024 Financial Results and Provides Corporate Update

Q32 Bio presents results from SIGNAL-AA Part 2a trial of bempikibart

2025-03-09T22:30:17.000Z - 1 year ago

Q32 Bio presents results from SIGNAL-AA Part 2a trial of bempikibart

Q32 Bio Presents Results from SIGNAL-AA Part A Clinical Trial Evaluating Bempikibart in Patients with Alopecia Areata at the 2025 American Academy of Dermatology Meeting

Mar 8, 2025, 11:00 AM EST - 1 year ago

Q32 Bio Presents Results from SIGNAL-AA Part A Clinical Trial Evaluating Bempikibart in Patients with Alopecia Areata at the 2025 American Academy of Dermatology Meeting

Q32 Bio Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 5, 2025, 11:50 AM EST - 1 year ago

Q32 Bio Transcript: TD Cowen 45th Annual Healthcare Conference

Q32 Bio Announces Late-Breaking Presentation of Results from SIGNAL-AA Part A Clinical Trial of Bempikibart in Alopecia Areata at the 2025 American Academy of Dermatology Annual Meeting

Feb 28, 2025, 9:00 AM EST - 1 year ago

Q32 Bio Announces Late-Breaking Presentation of Results from SIGNAL-AA Part A Clinical Trial of Bempikibart in Alopecia Areata at the 2025 American Academy of Dermatology Annual Meeting

Q32 Bio to Participate in Upcoming March Investor Conferences

Feb 26, 2025, 6:59 AM EST - 1 year ago

Q32 Bio to Participate in Upcoming March Investor Conferences

Q32 Bio Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025

Feb 11, 2025, 4:00 PM EST - 1 year ago

Q32 Bio Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025

Q32 Bio downgraded to Market Perform from Outperform at BMO Capital

2025-02-11T12:30:47.000Z - 1 year ago

Q32 Bio downgraded to Market Perform from Outperform at BMO Capital

Q32 Bio downgraded to Neutral from Overweight at Piper Sandler

2025-02-11T10:20:45.000Z - 1 year ago

Q32 Bio downgraded to Neutral from Overweight at Piper Sandler

Q32 Bio announces corporate restructuring to focus on bempikibart

2025-02-10T21:21:00.000Z - 1 year ago

Q32 Bio announces corporate restructuring to focus on bempikibart

Q32 Bio Announces Strategic Restructuring to Focus on Advancement of Bempikibart in Patients with Alopecia Areata

Feb 10, 2025, 4:05 PM EST - 1 year ago

Q32 Bio Announces Strategic Restructuring to Focus on Advancement of Bempikibart in Patients with Alopecia Areata

Q32 Bio to Participate in Oppenheimer's 35th Annual Healthcare Life Sciences Conference

Feb 4, 2025, 4:05 PM EST - 1 year ago

Q32 Bio to Participate in Oppenheimer's 35th Annual Healthcare Life Sciences Conference

Q32 Bio Provides Bempikibart Program Update, Including Next Steps for Advancing Alopecia Areata Development Program

Dec 10, 2024, 4:05 PM EST - 1 year ago

Q32 Bio Provides Bempikibart Program Update, Including Next Steps for Advancing Alopecia Areata Development Program

Q32 Bio Transcript: Guggenheim’s Inaugural Healthcare Innovation Conference

Nov 12, 2024, 10:00 AM EST - 1 year ago

Q32 Bio Transcript: Guggenheim’s Inaugural Healthcare Innovation Conference

Q32 Bio Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 7, 2024, 6:59 AM EST - 1 year ago

Q32 Bio Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Q32 Bio to Participate in Guggenheim's Inaugural Healthcare Innovation Conference

Nov 5, 2024, 6:59 AM EST - 1 year ago

Q32 Bio to Participate in Guggenheim's Inaugural Healthcare Innovation Conference

Q32 Bio to Present Tissue-Targeted Complement Inhibitor ADX-097 Positive Phase 1 Clinical Trial Results at the American Society of Nephrology Kidney Week 2024

Oct 14, 2024, 6:59 AM EDT - 1 year ago

Q32 Bio to Present Tissue-Targeted Complement Inhibitor ADX-097 Positive Phase 1 Clinical Trial Results at the American Society of Nephrology Kidney Week 2024

Q32 Bio Transcript: Stifel 2024 Immunology and Inflammation Virtual Summit

Sep 18, 2024, 11:30 AM EDT - 1 year ago

Q32 Bio Transcript: Stifel 2024 Immunology and Inflammation Virtual Summit

Q32 Bio Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 17, 2024, 3:40 PM EDT - 1 year ago

Q32 Bio Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Q32 Bio to Participate in Upcoming September Investor Conferences

Aug 29, 2024, 6:59 AM EDT - 1 year ago

Q32 Bio to Participate in Upcoming September Investor Conferences

Q32 Bio Announces Completion of Enrollment in the SIGNAL-AD Phase 2 Clinical Trial of Bempikibart for Atopic Dermatitis

Jul 9, 2024, 6:59 AM EDT - 2 years ago

Q32 Bio Announces Completion of Enrollment in the SIGNAL-AD Phase 2 Clinical Trial of Bempikibart for Atopic Dermatitis

Q32 Bio Joins Russell 3000® Index

Jul 1, 2024, 6:59 AM EDT - 2 years ago

Q32 Bio Joins Russell 3000® Index

Q32 Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 9, 2024, 6:59 AM EDT - 2 years ago

Q32 Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update

Q32 Bio Appoints Lee Kalowski as President & Chief Financial Officer

Apr 3, 2024, 7:00 AM EDT - 2 years ago

Q32 Bio Appoints Lee Kalowski as President & Chief Financial Officer

Q32 Bio Announces Closing of Merger with Homology Medicines and Concurrent Private Placement of $42 Million

Mar 25, 2024, 4:15 PM EDT - 2 years ago

Q32 Bio Announces Closing of Merger with Homology Medicines and Concurrent Private Placement of $42 Million

PenkeInvesting
PenkeInvesting May. 7 at 8:22 AM
Fundamental analysis of $QTTB (Q32 Bio Inc.) based on financial data and reported results. #QTTB
0 · Reply
MaximusRadius
MaximusRadius May. 5 at 7:26 PM
$QTTB new HOD
1 · Reply
MaximusRadius
MaximusRadius May. 5 at 7:07 PM
$QTTB 10 bagger coming
0 · Reply
MaximusRadius
MaximusRadius May. 5 at 7:00 PM
$QTTB once it breaks 8.05 there is no resistance till 50.00!
0 · Reply
MaximusRadius
MaximusRadius May. 5 at 6:35 PM
$QTTB Zacks gave it a strong buy rating so apparently it has something going for it.
0 · Reply
MaximusRadius
MaximusRadius May. 5 at 5:54 PM
$QTTB broke through the 5min and 15min 50 day moving average
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser May. 4 at 7:16 PM
$QTTB RSI: 40.60, MACD: -0.1369 Vol: 0.54, MA20: 5.76, MA50: 5.83 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Kwasy32
Kwasy32 May. 4 at 5:15 PM
$QTTB mark may 7 on ur calendar
2 · Reply
The_INFO_Dude
The_INFO_Dude May. 3 at 7:19 PM
$QTTB Waiting for this to touch $4’s again so I can triple down… I’m sure most on here will despise my comment but I don’t know anyone here so.. Meh 😂
0 · Reply
EdV3
EdV3 May. 2 at 6:25 PM
$QTTB Added this one to my watchlist. IL-7 MoA looks compelling but unproven; want to see the 36 week tld first before jumping in. This should show whether the higher dosing and longer treatment period yields better results than off label JAK inhibitors. If it looks good this is definitely one to consider as the safety profile looks a lot better than existing drugs. From there the headwind is financing a registrational P3. Interesting tute activity as well with Point 72 and Opaleye opening large positions within the last quarter.
0 · Reply
BiotechButterflies
BiotechButterflies May. 1 at 7:19 PM
$QTTB .understand the pullback given the large 75m ATM on such a small Cap... but it only gives me a cheaper entry point to top up ahead of the data release... if I can time that well... and heck - whats to complain about - dilution coming regardless assuming good data....this way they can maximise the companies capital raise....
1 · Reply
Kwasy32
Kwasy32 Apr. 29 at 8:01 PM
$QTTB waking up one day just to find out this stock has run 1500% in a day
0 · Reply
ash1012
ash1012 Apr. 27 at 2:45 PM
$QTTB tomo this will be $4.00
0 · Reply
BiotechButterflies
BiotechButterflies Apr. 27 at 1:44 PM
$QTTB they gotta raise after the AA readout coming imminently, so ATM used prudently is actully the ideal scenario instead of discounted offers to institutions - many who may avoid this is too small a Cap... so I'm supportive here..
1 · Reply
NotHopeJustFacts
NotHopeJustFacts Apr. 27 at 12:46 PM
$QTTB more dilution for a company that pretend to sell overpriced shampoo for bold people ? this is worthless and, after their failure with eczema, a scam
0 · Reply
Olivia_Strickland
Olivia_Strickland Apr. 24 at 10:03 PM
$QTTB down 14.64% AH after filing for a fresh $75M ATM offering. dilution stings on a $78M cap, that's basically the whole company. order book stacked 8x on the ask, no surprise. not touching this until the bleed stops.
2 · Reply
ffienimi
ffienimi Apr. 24 at 9:27 PM
$QTTB Q32 Bio filed a new prospectus supplement to sell up to USD 75 million of common stock through its at-the-market program with Cantor Fitzgerald. * Company completed its prior ATM tranche, selling USD 14.2 million of common stock under the earlier prospectus supplement. * Sales will continue under the existing Controlled Equity Offering sales agreement signed March 27, 2026. * Additional shares will be issued off Q32 Bio’s effective Form S-3 shelf registration statement
0 · Reply
GoCoogs
GoCoogs Apr. 24 at 9:20 PM
$QTTB WTH is going on with this after-hours?
0 · Reply
scoon42
scoon42 Apr. 21 at 1:26 PM
$QTTB $8 incoming today IMO!
0 · Reply
Stef_DL
Stef_DL Apr. 21 at 12:58 PM
$QTTB A lot of live in the green party. Let's see what this bring at opening 🤔.
0 · Reply
STACKD0E
STACKD0E Apr. 21 at 12:35 PM
$QTTB $SLDP $PRLD $LOBO
1 · Reply
scoon42
scoon42 Apr. 21 at 12:09 PM
$QTTB Something’s Brewing!
0 · Reply